RxDoctor Payments Data

Jenna Roney, OD

Optometrist · Burlington, NCNPI 1518484617

Payments from drug & device makers

$3,621in general payments, 2019–2025

Across 81 payments — averaging $44.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Vision Care, Inc.$2K
  • Alcon$479
  • Bausch & Lomb Americas Inc.$418
  • Tarsus Pharmaceuticals, Inc.$297
  • Coopervision Inc.$224
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$111
  • plus $552 from 10 others

What the payments were for

  • Travel & lodging$1,11331%
  • Food & beverage$2,48969%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,621 in reported general payments places this provider in the 80th percentile of 1,326 optometrist providers in North Carolina.

See all optometrist providers in North Carolina

Medicare billing

Part B allowed, 2024
$20,309
Medicare patients
67
Services billed
990

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine22$29,521
XdemvyLotilaner15$28,198
TyrvayaVarenicline Tartrate24$15,411
MieboPerfluorohexyloctane/Pf21$15,131
IyuzehLatanoprost/Pf22$9,887
Fluorometholone24$1,500
Doxycycline Monohydrate23$835
ValacyclovirValacyclovir Hcl13$271
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha20$258
Latanoprost21$184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$17$29,52122 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$297$28,19815 claims
Oyster Point Pharma, Inc.Tyrvaya$95$15,41124 claims
Bausch & Lomb Americas Inc.Miebo$418$15,13121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,326 optometrist providers in North Carolina.

Other optometrist in Burlington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →